Results 231 to 240 of about 939,495 (280)

Preoperative selpercatinib induces major pathological response in a patient with stage IIIA, RET fusion-positive non-small cell lung cancer: A case report. [PDF]

Medicine (Baltimore)
Breitenecker K, Fabikan H, Weinlinger C, Krenbek D, Klikovits T, Watzka S, Valipour A, Hochmair MJ.   +7 more
europepmc   +1 more source

Nucleic Acids as Emerging Regulators of Calcium Phosphate Biomineralization

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Calcium phosphate biomineralization has traditionally been considered a protein‐regulated process. This review highlights the emerging role of nucleic acids, which interact with mineral phases through adsorption, coprecipitation, and templating, thereby influencing crystal nucleation and growth.
Fanny Duhalde, Jessem Landoulsi, Xavier Houard   +2 more
wiley   +1 more source

Molecular Characterisations and the Association with Clinical Factors in <i>RET</i> Fusion-Positive NSCLC: A Retrospective Study of the Single Center Cohort. [PDF]

Cancer Manag Res
Li X, Zhao P, Cui H, Zhang T, Sun W, Li H.   +5 more
europepmc   +1 more source

A Case Report on Pericardial Effusion Associated With Selpercatinib in the First Patient With Rearranged During Transfection (RET) Fusion-Positive Lung Cancer. [PDF]

Cureus
Shiraishi T, Isoshima Y, Tahara M, Jotatsu T, Yatera K.   +4 more
europepmc   +1 more source

Selpercatinib as First-Line Therapy in a 9-Month-Old Infant With Metastatic <i>RET</i> Fusion-Positive Sarcoma: A Case Report. [PDF]

JCO Precis Oncol
Mast AS, Leuschner U, Schulte S, Mezger M, Ebinger M.   +4 more
europepmc   +1 more source

BAY 43-9006 inhibition of oncogenic RET proteins: activity on gate-keeper mutants [PDF]

, 2007
Anaganti, Suresh
core  

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib. [PDF]

Front Genet
Jin F, Wang C, Yang F, Wang S, Wang F.
europepmc   +1 more source

An emerging melody composed of the notes from structural variants - Comment on 'The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis' by Chen et al. [PDF]

Transl Oncol
Wu L, Zhou Q, Lu C.
europepmc   +1 more source

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer. [PDF]

Front Med (Lausanne)
Wang L, You Y, He W, Hou Y, Li L, Wang L, Jiang C, Yi J, Xia Y, Xia L.   +9 more
europepmc   +1 more source

Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression. [PDF]

Front Pharmacol
Bao H, Zhang J, Wang Y, Chen Z, Luo X, Li T, Su H, Bao H, Cao X, Lin L.   +9 more
europepmc   +1 more source